<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01984931</url>
  </required_header>
  <id_info>
    <org_study_id>CMH-2013-02</org_study_id>
    <nct_id>NCT01984931</nct_id>
  </id_info>
  <brief_title>Study of Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)for Treatment of Post Operative Nausea and Vomiting</brief_title>
  <official_title>Trimebutine Maleate (NEWBUTIN SR 300 mg Tab) as a Prophylactic Anti-emetic Drug for Patients Who Underwent Arthroscopic Rotator Cuff Repair: a Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CM Chungmu Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korea United Pharm. Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CM Chungmu Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine if giving Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)orally will
      be effective as a prophylactic anti-emetic drug for patients who underwent arthroscopic
      rotator cuff repair under general anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients will be divided in two groups using a computer generated randomization software.
      The first will be the MACPERAN group (controlled) and the other will be the NEWBUTIN group
      (variable). The controlled group will be treated with post-operative regimen in accordance
      with the standard protocol of the Chungmu Hospital, MACPERAN(Metoclopramide hydrochloride
      monohydrate 8.46 mg/2ml/A) thru IV twice in a day while the variable group will be given a
      single dose of NEWBUTIN SR 300 mg Tab orally one hour prior to the said operation time and
      another 300 mg orally as soon as the patient wakes post operatively.

      A clinical research coordinator will monitor the patient until 48 hours post-operative. First
      time frame will be from 0-2 hours once patient is transferred to the ward followed by 2 hours
      to 24 hours and 24-48 hours post ward transfer. All patients will be assessed using the
      simplified risk score of Apfel et al. to determine who have the risk factors for PONV. The
      episodes of nausea and vomiting will be recorded taking note of its intensity and frequency
      on the said three time frames. Nausea is defined as a subjectively unpleasant sensation
      associated with an awareness of the urge to vomit; vomiting is defined as the forceful
      expulsion of gastric contents through the mouth. As retching is similar to vomiting in all
      aspects, except for the expulsion of gastric contents, it was considered as vomiting. The
      efficacy of anti-emetic medication (NEWBUTIN 300 mg/tab) will be assessed by monitoring the
      frequency and severity of nausea, vomiting, and PONV (which was regarded as the primary
      outcome). The severity of nausea will be graded on a four-point scale, where 0= no nausea, 1=
      mild nausea, 2= moderate nausea, and 3= severe nausea.Then the frequency will be assessed by
      monitoring how often the patient experienced these episodes (nausea and vomiting)during the
      said time frames.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of nausea after taking Trimebutine Maleate as a prophylactic medication</measure>
    <time_frame>0-48 hours post rotator cuff repair</time_frame>
    <description>The severity of nausea will be graded on a four-point scale. 0- no nausea (can do all tasks). 1- mild nausea (can talk and answer questions appropriately,sit, stand but can't walk). 2- moderate nausea (can talk and but answer questions inappropriately, sit but can't stand and walk). 3- severe nausea (don't talk and answer questions, prefers lying down, cannot sit, stand and walk).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of PONV after taking Trimebutine Maleate as a prophylactic medication</measure>
    <time_frame>0-48 hours post rotator cuff repair</time_frame>
    <description>Frequency is how often the patient experienced the episodes of nausea and vomiting in a given time period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Nausea</condition>
  <condition>Vomiting</condition>
  <arm_group>
    <arm_group_label>Trimebutine Maleate 300 mg Tab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of NEWBUTIN SR 300 mg Tab will be given orally one hour prior to the said operation time and another 300 mg orally as soon as the patient wakes post operatively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoclopramide hydrochloride monohydrate 8.46 mg/2ml/A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anti-emetic medication protocol of Chungmu Hospital includes MACPERAN (Metoclopramide hydrochloride monohydrate 8.46 mg/2ml/A)thru IV twice in a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)</intervention_name>
    <description>Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)is a noncompetitive spasmolytic agent. It possesses moderate opiate receptor affinity and has marked anti-serotonin activity especially on'M' receptors. A single dose of NEWBUTIN SR 300 mg Tab orally will be given one hour prior to the said operation time and another 300 mg orally as soon as the patient wakes post operatively.</description>
    <arm_group_label>Trimebutine Maleate 300 mg Tab</arm_group_label>
    <other_name>•Antinime</other_name>
    <other_name>•Cineprac</other_name>
    <other_name>•Colixane B (Trimebutine and Bromazepam)</other_name>
    <other_name>•Colixane Prokin (Trimebutine and Mosapride)</other_name>
    <other_name>•Colixane</other_name>
    <other_name>•Colonix B (Trimebutine and Bromazepam)</other_name>
    <other_name>•Colonix</other_name>
    <other_name>•Colospasmyl</other_name>
    <other_name>•Colperin</other_name>
    <other_name>•Crobutin</other_name>
    <other_name>•Debricol</other_name>
    <other_name>•Debridat</other_name>
    <other_name>•Débridat</other_name>
    <other_name>•Eumotrix</other_name>
    <other_name>•Ibuproct (Trimebutine and Ruscogenin)</other_name>
    <other_name>•Ibutin</other_name>
    <other_name>•Libertrim</other_name>
    <other_name>•Libertrim Pediátrico (pediatric)</other_name>
    <other_name>•Libertrim SDP (Trimebutine and Simeticone)</other_name>
    <other_name>•Libertrim SII (Trimebutine and Simeticone)</other_name>
    <other_name>•Muvett</other_name>
    <other_name>•Polybutine</other_name>
    <other_name>•Prescol</other_name>
    <other_name>•Proctolog (Trimebutine and Ruscogenin)</other_name>
    <other_name>•Promebutin</other_name>
    <other_name>•Ruscolog (Trimebutine and Ruscogenin)</other_name>
    <other_name>•Tribux</other_name>
    <other_name>•Trimebutin</other_name>
    <other_name>•Trimebutina Genfar</other_name>
    <other_name>•Trimebutina La Santé</other_name>
    <other_name>•Trimebutina</other_name>
    <other_name>•Trimebutino Andromaco</other_name>
    <other_name>•Trimedine</other_name>
    <other_name>•Trimegam</other_name>
    <other_name>•Trimet</other_name>
    <other_name>•Altrip</other_name>
    <other_name>•Apo-Trimebutine</other_name>
    <other_name>•Biorgan B (Trimebutine and Bromazepam)</other_name>
    <other_name>•Biorgan</other_name>
    <other_name>•Bumetin</other_name>
    <other_name>•Butikinon</other_name>
    <other_name>•Cerekinon</other_name>
    <other_name>•Cerenamelin</other_name>
    <other_name>•Colobutine</other_name>
    <other_name>•Colypan</other_name>
    <other_name>•Debretin</other_name>
    <other_name>•Debricalm</other_name>
    <other_name>•Debridat AP</other_name>
    <other_name>•Debridat B (Trimebutine and Bromazepam)</other_name>
    <other_name>•Debridat Fort</other_name>
    <other_name>•Debrum (Trimebutine and Medazepam)</other_name>
    <other_name>•Derispan</other_name>
    <other_name>•Digerent</other_name>
    <other_name>•Diway</other_name>
    <other_name>•Dolpic</other_name>
    <other_name>•Eumotil</other_name>
    <other_name>•Eumotil-S (Trimebutine and Simeticone)</other_name>
    <other_name>•Eumotil-T (Trimebutine and Bromazepam)</other_name>
    <other_name>•Eutransil</other_name>
    <other_name>•Fenatrop</other_name>
    <other_name>•Garapepsin</other_name>
    <other_name>•Gaspat</other_name>
    <other_name>•Gismotal</other_name>
    <other_name>•Liement</other_name>
    <other_name>•Mebucolon</other_name>
    <other_name>•Mebutit</other_name>
    <other_name>•Miopropan</other_name>
    <other_name>•Modulon</other_name>
    <other_name>•Mustrick</other_name>
    <other_name>•Muvett S (Trimebutine and Simeticone)</other_name>
    <other_name>•Newbutin SR</other_name>
    <other_name>•Ni Wei Fu</other_name>
    <other_name>•Pelkysil</other_name>
    <other_name>•Pilemain</other_name>
    <other_name>•Polibutin</other_name>
    <other_name>•Recutin</other_name>
    <other_name>•Rekelat</other_name>
    <other_name>•Rui Jian</other_name>
    <other_name>•Sakion</other_name>
    <other_name>•Selumito</other_name>
    <other_name>•Shuang Di</other_name>
    <other_name>•Spabutine</other_name>
    <other_name>•Spamoin</other_name>
    <other_name>•Supeslone</other_name>
    <other_name>•Sutent</other_name>
    <other_name>•Tarabutine</other_name>
    <other_name>•Tefmetin</other_name>
    <other_name>•Tidomel</other_name>
    <other_name>•Timotor</other_name>
    <other_name>•Transacalm</other_name>
    <other_name>•Tribudat Forte</other_name>
    <other_name>•Tribudat</other_name>
    <other_name>•Tributin</other_name>
    <other_name>•Tricin</other_name>
    <other_name>•Tridat</other_name>
    <other_name>•Trienter</other_name>
    <other_name>•Trim</other_name>
    <other_name>•Trimebutin Maleate Taiyo</other_name>
    <other_name>•Trimebutina Angenerico</other_name>
    <other_name>•Trimebutina Colmed</other_name>
    <other_name>•Trimebutina maleato</other_name>
    <other_name>•Trimebutina MK</other_name>
    <other_name>•Trimébutine Actavis</other_name>
    <other_name>•Trimébutine Almus</other_name>
    <other_name>•Trimébutine ALS</other_name>
    <other_name>•Trimébutine Arrow</other_name>
    <other_name>•Trimébutine Biogaran</other_name>
    <other_name>•Trimébutine CristerS</other_name>
    <other_name>•Trimébutine EG</other_name>
    <other_name>•Trimébutine Evolugen</other_name>
    <other_name>•Trimébutine Isomed</other_name>
    <other_name>•Trimébutine maléate RPG</other_name>
    <other_name>•Trimébutine Mylan</other_name>
    <other_name>•Trimébutine Pfizer</other_name>
    <other_name>•Trimébutine Qualimed</other_name>
    <other_name>•Trimébutine Ranbaxy</other_name>
    <other_name>•Trimébutine Ratio</other_name>
    <other_name>•Trimébutine Ratiopharm</other_name>
    <other_name>•Trimébutine Sandoz</other_name>
    <other_name>•Trimébutine Teva</other_name>
    <other_name>•Trimébutine Zentiva</other_name>
    <other_name>•Trimébutine Zydus</other_name>
    <other_name>•Trimebutino Maleato</other_name>
    <other_name>•Trimedat</other_name>
    <other_name>•Trishi</other_name>
    <other_name>•VeM</other_name>
    <other_name>•Yuan Sheng Li Wei</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoclopramide hydrochloride monohydrate</intervention_name>
    <arm_group_label>Metoclopramide hydrochloride monohydrate 8.46 mg/2ml/A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  post arthroscopic cuff repair patient previously diagnosed with small to large rotator
             cuff tear thru MRI

        Exclusion Criteria:

          -  above 70 years old

          -  massive rotator cuff tear
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paolo Alan B Tabar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Education Center of Shoulder, Elbow Surgery: Chungmu Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sang Hoon Lhee, MD, PhD</last_name>
    <phone>+82 (2) 2068/4525</phone>
    <email>cmirb@naver.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chungmu General Hopsital</name>
      <address>
        <city>Seoul</city>
        <state>Yeongdeungpo-gu</state>
        <zip>150-034</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang Hoon Lhee, MD, Phd</last_name>
      <phone>+82 (2) 2068/4525</phone>
      <email>cmirb@naver.com</email>
    </contact>
    <investigator>
      <last_name>Paolo Alan B Tabar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2013</study_first_submitted>
  <study_first_submitted_qc>November 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2013</study_first_posted>
  <last_update_submitted>November 8, 2013</last_update_submitted>
  <last_update_submitted_qc>November 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CM Chungmu Hospital</investigator_affiliation>
    <investigator_full_name>Sang-Hoon Lhee</investigator_full_name>
    <investigator_title>Director of CM Chungmu Hospital</investigator_title>
  </responsible_party>
  <keyword>post operative nausea and vomiting</keyword>
  <keyword>Trimebutine Maleate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maleic acid</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
    <mesh_term>Antiemetics</mesh_term>
    <mesh_term>Trimebutine</mesh_term>
    <mesh_term>Bromazepam</mesh_term>
    <mesh_term>Simethicone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

